FDA Speeds Up Alzheimer's Brain Test with Less Red Tape
Published Date: 4/22/2026
Rule
Summary
The FDA is officially putting the Alzheimer's Disease Pathology Assessment Test into a safer, easier-to-manage category called Class II, starting April 22, 2026. This change helps patients get access to this important test faster by cutting down on red tape, while still making sure it’s safe and works well. Medical device makers will find it simpler and less costly to bring this test to market.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Device Reclassified to Class II
The FDA has classified the Alzheimer's disease pathology assessment test as Class II (special controls), effective April 22, 2026. FDA says this classification reduces regulatory burdens and will make it simpler and less costly for makers to bring this test to market.
Enables Predicate Use for Future Devices
Because FDA classified this device via the De Novo process, the device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of De Novo or premarket approval. FDA issued the classification order on May 4, 2022 and codified it at 21 CFR 866.5840.
510(k) Submission and Special Controls Required
Alzheimer's disease pathology assessment tests remain subject to premarket notification under section 510(k) and must meet special controls codified at 21 CFR 866.5840. Required special controls include detailed design verification and validation studies (analytical and clinical performance, reference intervals, specimen stability) and specific labeling elements.
Patients May Get Faster Access To Test
FDA says classifying the test into Class II will enhance patients' access to the Alzheimer's disease pathology assessment test by reducing regulatory burdens; the order is effective April 22, 2026. The test is intended to assess amyloid plaques or neurofibrillary tangles in patients with cognitive impairment to increase diagnostic certainty when used with clinical assessment.
Labeling Limits Use and Interpretation
Labels for the device must state the intended measurand(s), specify the populations and clinical contexts for use, and include limiting statements that the test is not for stand-alone use, is not established for predicting dementia or monitoring therapy, and that a positive result indicates amyloid plaques or tangles but does not establish a diagnosis. These labeling requirements are part of the special controls in 21 CFR 866.5840.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07808 — Airworthiness Directives; The Boeing Company Airplanes
The FAA is rolling out a new safety rule for Boeing 747-400 planes with certain upgrades after finding a busted oxygen hose and damaged wiring. Airlines must inspect and fix any worn hoses or wiring by May 7, 2026, to keep flights safe. This might cost some time and money but keeps crews and passengers protected.
Next: 2026-07861 — Medical Devices; Ophthalmic Devices; Classification of the Digital Therapy Device for Amblyopia
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer, starting April 22, 2026. Device makers will benefit from simpler rules, saving time and money while keeping safety top-notch.